The Asia Pacific Center of Excellence has a deep knowledge of the nuanced differences within each market of the region, and understand when it is beneficial or necessary to gather insights from stakeholders beyond payers and physicians to answer our client’s questions.
Showing 5 of 9 posts
August 13, 2019 | Blogs
Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.
June 24, 2019 | Blogs
CBPartners believes that Hong Kong’s loosening of its IPO listing criteria will result in material growth for the local biotech market; however, in mainland China, infrastructural obstacles remain (e.g., insufficient industry talent) which may slow biotech development regulatory incentives. CBPartners' Asia-Pacific Center of Excellence will continue to monitor this IPO evolution.
January 14, 2019 | Blogs
September 9, 2018 | Blogs
When the engine of innovation gets the green light of marketing authorisation, it is typically first in the USA, and sometimes for the EMA’s (European Medicines Agency) jurisdiction over much of Europe. Unfortunately, China is too often one the last markets among the major and highest-tier of emerging markets to be considered for broad patient access. CBPartners explores the evolving reimbursement dynamics in China.